Sunday, 22 May 2022

Curocell opens 'CAR-T Manufacturing GMP Facility' in Korea

24 December 2021 | News

Curocell is developing OVIS technology with the goal of improving clinical efficacy of CAR-T therapies

image credit- prnewswire

image credit- prnewswire

Curocell, currently on PhaseⅠCAR-T Therapy clinical trial with CRC01 (anbalcabtagene autoleucel), has recently broken ground for the new CAR-T Centre in Dungok Residential & Industrial Area in Daejeon International Science & Business Belt, in South Korea.

The GMP Facility for commercial manufacturing CAR-T Cell therapy and R&D Centre for further pipeline development are constituting the 17,325 square-meter site of CAR-T Centre.

By the first half of 2023, construction is expected to be completed and in 2024, when the CAR-T Centre is fully operational, supply of advanced cure should be possible for patients in pain. Also, Curocell is expecting to expand their business to global market by in-housing all processes of CAR-T therapy development and production.

CRC01, recognized CD19 and is based on OVIS™, a first-in-class CAR-T platform. OVIS™ technology downregulates PD1 and TIGIT expression on CAR-T cells. Through overcoming the immune suppression by PD-1 and TIGIT ligands, OVIS™ CAR-T has superior cytotoxicity to tumor cells in the tumor microenvironment. Phase II clinical trial of CRC01 will start in South Korea in the first half of 2022.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account